BRIEF-Veru Enrolls First Patients In Phase 2B Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss

Reuters04-30

April 30 (Reuters) - Veru Inc :

* VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS

* VERU INC: TOPLINE CLINICAL DATA EXPECTED IN Q4 CALENDAR YEAR 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431340022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-30 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431340022","market":"us","top_or_hot":-1,"title":"BRIEF-Veru Enrolls First Patients In Phase 2B Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss","media":"Reuters","content":"<html><body><p>April 30 (Reuters) - Veru Inc   :</p><p>   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS</p><p>   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS</p><p>   * VERU INC: TOPLINE CLINICAL DATA EXPECTED IN Q4 CALENDAR YEAR 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Veru Enrolls First Patients In Phase 2B Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Veru Enrolls First Patients In Phase 2B Clinical Trial Of Enobosarm And Semaglutide Combination For High Quality Weight Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 30 (Reuters) - Veru Inc   :   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS   * VERU ENROLLS FIRST PATIENTS IN ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2431340022","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431340022","pubTimestamp":1714482671,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 30  - Veru Inc   :   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS   * VERU INC: TOPLINE CLINICAL DATA EXPECTED IN Q4 CALENDAR YEAR 2024Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4183":"个人用品","VERU":"Veru Inc.","BK4557":"大麻股"},"translate_title":"简介-Veru招募首批患者参加依诺波沙姆和Semaglutide联合用于高质量减肥的2B期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERU":0.9},"content_text":"April 30 (Reuters) - Veru Inc   :   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS   * VERU ENROLLS FIRST PATIENTS IN PHASE 2B CLINICAL TRIAL OF ENOBOSARM AND SEMAGLUTIDE COMBINATION FOR HIGH QUALITY WEIGHT LOSS   * VERU INC: TOPLINE CLINICAL DATA EXPECTED IN Q4 CALENDAR YEAR 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431340022"}